Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

MLA

Bahriye Aktas, et al. “Efficacy and Safety of Nab-Paclitaxel 125 Mg/M2 and Nab-Paclitaxel 150 Mg/M2 Compared to Paclitaxel in Early High-Risk Breast Cancer. Results from the Neoadjuvant Randomized GeparSepto Study (GBG 69).” Breast Cancer Research and Treatment, vol. 163, Mar. 2017, pp. 495–506. EBSCOhost, https://doi.org/10.1007/s10549-017-4200-1.

APA

Bahriye Aktas, Michael Untch, Serban-Dan Costa, Jenny Furlanetto, Sherko Kümmel, John Hackmann, Stefan Paepke, Mathias Warm, Bernd Gerber, Jens Uwe Blohmer, Andreas Schneeweiss, Sabine Schmatloch, Sibylle Loibl, Claus Hanusch, Carsten Denkert, Marianne Just, Christian Jackisch, Valentina Nekljudova, Gunter von Minckwitz, … Hermann Wiebringhaus. (2017). Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Research and Treatment, 163, 495–506. https://doi.org/10.1007/s10549-017-4200-1

Chicago

Bahriye Aktas, Michael Untch, Serban-Dan Costa, Jenny Furlanetto, Sherko Kümmel, John Hackmann, Stefan Paepke, et al. 2017. “Efficacy and Safety of Nab-Paclitaxel 125 Mg/M2 and Nab-Paclitaxel 150 Mg/M2 Compared to Paclitaxel in Early High-Risk Breast Cancer. Results from the Neoadjuvant Randomized GeparSepto Study (GBG 69).” Breast Cancer Research and Treatment 163 (March): 495–506. doi:10.1007/s10549-017-4200-1.